DZ BANK AG analyst Elmar Kraus maintained a Buy rating on Roche Holding AG today. The company’s shares closed yesterday at $351.28.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...
In a report released today, Matthew Weston from UBS maintained a Buy rating on Roche Holding AG, with a price target of CHF314.00. The company’s shares closed last Friday at $357.00.Elevate Your Investing...
In a report released today, Richard Vosser from J.P. Morgan maintained a Sell rating on Roche Holding AG, with a price target of CHF230.00. The company’s shares closed last Friday at $357.00.Elevate...
In a report released today, Yihan Li from Barclays maintained a Hold rating on Roche Holding AG, with a price target of CHF275.00. The company’s shares closed yesterday at $362.85.Elevate Your Investing...
J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG today and set a price target of CHF230.00. The company’s shares opened today at $360.22.Elevate Your Investing Strategy:...
Goldman Sachs analyst Rajan Sharma maintained a Sell rating on Roche Holding AG today and set a price target of CHF248.00. The company’s shares closed last Friday at $360.15.Elevate Your Investing Strategy:...
In a report released yesterday, Rajesh Kumar from HSBC upgraded Roche Holding AG to a Buy, with a price target of CHF320.00. The company’s shares closed yesterday at $353.22.Elevate Your Investing Strategy:...
When a microcap %Biotech transitions from obscurity to the Nasdaq Capital Market, fireworks are common. The move often signals a pivotal moment in the company's growth trajectory, opening the door to broader...
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.